共 50 条
- [31] The importance of histology when evaluating the cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced non-small cell lung cancerJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Muehlenbein, C. E.Klein, R. W.Liepa, A. M.Babineaux, S. M.Wielage, R. C.Schwartzberg, L. S.
- [32] EFFICACY AND SAFETY OF CISPLATIN/PEMETREXED AS FIRST-LINE TREATMENT FOR JAPANESE PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCERRESPIROLOGY, 2013, 18 : 83 - 83Yamaguchi, TeppeiNakanishi, ToruHayashi, MasamichiIsogai, SumitoHoshino, TamiMieno, YukiUozu, SakurakoMorishita, MarikoOkamura, TakuyaTakeyama, TomokoMinezawa, TomoyukiMorikawa, SayakoNiwa, YoshikazuOkazawa, MitsushiImaizumi, Kazuyoshi
- [33] Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancerTUMORI JOURNAL, 2013, 99 (06): : 650 - 655Piacentini, PaoloGreco, FilippoMercanti, AnnaTrolese, Anna RitaDurante, EmiliaMoratello, GiacomoTognetto, MicheleFurini, LaraGiuliani, JacopoBonetti, Andrea
- [34] Anlotinib combined with pemetrexed and carboplatin as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC): ALTER L012.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Wang, QimingYang, XiuliMa, TianjiangYang, QiuminZhang, ChenghuiChen, Yunfang
- [35] The use of pemetrexed for the first-line treatment of non-small cell lung cancerLUNG CANCER, 2014, 83 : S13 - S13Silva, S.Colquitt, J.Hatton, M. Q.Mohanamurali, J.Lee, C.Danson, S.Fisher, P.Woll, P.
- [36] Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Chung, CarmenIsaranuwatchai, WanrudeeDi Maio, MassimoJiang, HaiyanLau, AntheaHoch, Jeffrey S.Feld, RonaldTsao, Ming SoundGridelli, CesareCiardiello, FortunatoButts, Charles AndrewGallo, CiroPerrone, FrancescoLeighl, Natasha B.
- [37] ECONOMIC ANALYSIS OF TORCH: ERLOTINIB VERSUS CISPLATIN AND GEMCITABINE AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S602 - S603Chung, CarmenJiang, HaiyanIsaranuwatchai, WanrudeeDi Maio, Mas-SimoLau, AntheaHoch, JeffreyFeld, RonaldTsao, Ming-SoundGridelli, CesareGallo, CiroCiardiello, FortunatoButts, Charles A.Perrone, FrancescoLeighl, Natasha B.
- [38] Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL TrialCLINICAL LUNG CANCER, 2017, 18 (04) : E289 - E296Park, Cheol-KyuOh, In-JaeKim, Kyu-SikChoi, Yoo-DukJang, Tae-WonKim, Youn-SeupLee, Kwan-HoShin, Kyeong-CheolJung, Chi YoungYang, Sei-HoonRyu, Jeong-SeonJang, Seung-HunYoo, Seung-SooYong, Suk-JoongLee, Kye YoungIn, Kwang-HoLee, Min-KiKim, Young-Chul
- [39] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)ONKOLOGIE, 2003, 26 : 26 - 32Manegold, C
- [40] PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT OR PEMETREXED CONTINUATION MAINTENANCE TREATMENT IN ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A REPORT OF PATIENT SAFETY IN THE PARAMOUNT TRIALJOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S842 - S843De Marinis, FilippoGridelli, CesareDediu, MirceaThomas, MichaelPujol, Jean-LoisMolinier, OlivierReck, MartinSahoo, Tarini P.San Antonio, BelenJohn, William J.Zimmermann, Annamaria H.Chouaki, NadiaVisseren-Grul, CarlaPaz-Arez, Luis G.